Sun.Dec 10, 2023

article thumbnail

‘No tolerance for failure’: An oral history of the first CRISPR medicine

BioPharma Dive

A new sickle cell disease therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals is now approved in the U.S. and U.K. This is the story of how it came to be.

142
142
article thumbnail

PulmCrit: New ARDS guidelines reveal a shambolic state of affairs

EMCrit Project

Within the past year, two major societies have released guidelines on ARDS: the ATS (American Thoracic Society) and the ESICM (European Society of Intensive Care Medicine). Don’t be fooled by their names – both of these organizations are fundamentally international in scope. Some authors on the ATS document were from Europe, and similarly some authors […] EMCrit Project by Josh Farkas.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Decoding Pfizer’s Portfolio: A New Model for Precision in Pharma Investments

Drug Patent Watch

In the ever-evolving landscape of the biotech and pharmaceutical sectors, accurate valuation of post-revenue drug assets stands as the linchpin for informed and strategic decision-making. The significance of this valuation… The post Decoding Pfizer’s Portfolio: A New Model for Precision in Pharma Investments appeared first on DrugPatentWatch - Make Better Decisions.

111
111
article thumbnail

Clonidine Versus Guanfacine: ADHD Management

Med Ed 101

This article will discuss two of the three commonly used non-stimulant medications for the management of ADHD and ADHD-related symptoms. We will primarily focus on comparing clonidine versus guanfacine in pediatric patients. As pharmacies deal with shortages of more and more stimulant medications commonly used to treat ADHD in children, it may come up more […] The post Clonidine Versus Guanfacine: ADHD Management appeared first on Med Ed 101.

105
105
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Pfizer marks progress for successor sickle cell drug at ASH

BioPharma Dive

While new gene therapies for the blood disease grabbed headlines at ASH, Pfizer presented fresh data for an oral drug meant to build on its marketed therapy Oxbryta.

70
article thumbnail

Rigel, MD Anderson partner to expand REZLIDHIA assessment in AML

Pharmaceutical Business Review

AML is a fast-developing cancer originating in the blood and bone marrow, impacting myeloid cells that typically transform into different types of mature blood cells. REZLIDHIA is a selective, potent, oral, small-molecule inhibitor of mutated IDH1 (mIDH1) intended for binding and inhibiting mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.

59

More Trending

article thumbnail

Diarrhoea

RX Note

Introduction Opposite to constipation , diarrhoea refers to an increase in frequency of the passage of abnormally soft or watery stools relative to the usual bowel for that individual. It is usually a symptom of gastrointestinal infection, which can be caused by a variety of bacterial, viral and parasitic organisms. Most patients will present to the community pharmacy with a self-diagnosis of acute diarrhoea (rapid onset, lasts 14 days) - Crohn's disease?

article thumbnail

Episode 877: Sedation and Analgesia Statements From the AHA/NCS Scientific Statement on Critical Care Management of Patients After Cardiac Arrest

Pharmacy Joe

In this episode, I’ll discuss the AHA/NCS scientific statement on critical care management of patients after cardiac arrest. Episode 877: Sedation and Analgesia Statements From the AHA/NCS Scientific Statement on Critical Care Management of Patients After Cardiac Arrest Subscribe on iTunes , Android , or Stitcher There is a lack of high-quality published research to support the critical care management of patients after cardiac arrest, and as a result there are few guideline recommendations in t

article thumbnail

Pharmaceutical Executive: December 2023 Issue (PDF)

PharmExec

Click the title above for a link to open the Pharmaceutical Executive November 2023 issue in an interactive PDF format.

52
article thumbnail

Gender Gap in NIH-Awarded Research Grants Persists in the Field of Non-Malignant Hematology

Pharmacy Times

The study results shine a light on the potential need for further policy changes that promote gender equity and bridge the gap in R01 funding awarded to female applicants.

52
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Chemist Warehouse merger with Sigma to create $8.8bn pharmacy group

The Guardian - Pharmaceutical Industry

Proposed merger with smaller competitor Sigma and stock market listing would unlock billions of dollars for founders of discount pharmacy chain Chemist Warehouse Follow our Australia news live blog for latest updates Get our morning and afternoon news emails , free app or daily news podcast Chemist Warehouse will become a publicly traded company through a merger with Sigma Healthcare, creating a retailing giant and unlocking billions of dollars for the founders of the discount pharmacy chain.

42
article thumbnail

Golidocitinib Demonstrates Significant Survival Benefits For Patients with Peripheral T-cell Lymphoma

Pharmacy Times

Median overall survival is set to be more than 2 years, which is more than double the overall survival of current frontline therapies.

58
article thumbnail

CSL sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for CSL here.

52
article thumbnail

ASH President Speaks on Pharmacists, Novel Innovations in Hematology

Pharmacy Times

He also provides insight for students training in classical hematology, oncology hematology, or oncology pharmacy.

52
article thumbnail

CSL sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for CSL here.

52
article thumbnail

Reflecting on 2023

PharmExec

Another year in the books.

52
article thumbnail

United Laboratories International sees highest patent filings and grants during July in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for United Laboratories International here.

40
article thumbnail

Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL

Pharmacy Times

This is the first trial to show that a MRD-guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of PFS and OS.

article thumbnail

United Laboratories International sees highest patent filings and grants during July in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for United Laboratories International here.

40
article thumbnail

Pharmaceutical companies with the most ‘New Chemical Entity’ drugs

Drug Patent Watch

Five years of exclusivity is provided for drugs which do not contain active molecules that have appeared in previously-approved drugs. This is one of the longest exclusivity terms provided by… The post Pharmaceutical companies with the most ‘New Chemical Entity’ drugs appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Sun Pharmaceutical Industries sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Sun Pharmaceutical Industries here.

52
article thumbnail

Steps required to control packaging materials in pharmaceutical

GMPSOP

Steps required to control packaging materials in pharmaceutical Pharmaceuticals quality assurance & validation procedures GMPSOP Steps required to control packaging materials in pharmaceutical Last Updated on December 10, 2023 Prev PREVIOUS POST Table of Contents Pharmaceutical manufacturers implement numerous processes to control packaging materials to avoid costly mix-ups.

article thumbnail

Sun Pharmaceutical Industries sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Sun Pharmaceutical Industries here.

52
article thumbnail

Hisamitsu Pharmaceutical sees highest patent filings and grants during September in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Hisamitsu Pharmaceutical here.

40
article thumbnail

Hisamitsu Pharmaceutical sees highest patent filings and grants during September in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Hisamitsu Pharmaceutical here.

40
article thumbnail

Cosmo Pharmaceuticals sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Cosmo Pharmaceuticals here.

40
article thumbnail

Cosmo Pharmaceuticals sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Cosmo Pharmaceuticals here.

40
article thumbnail

Daewoong sees highest patent filings and grants during July in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Daewoong here.

40
article thumbnail

Almirall sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Almirall here.

40
article thumbnail

Daewoong sees highest patent filings and grants during July in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Daewoong here.

40
article thumbnail

Almirall sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Almirall here.

40
article thumbnail

Otsuka sees highest patent filings and grants during July in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Otsuka here.

40
article thumbnail

Otsuka sees highest patent filings and grants during July in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Otsuka here.

40
article thumbnail

Lupin sees highest patent filings and grants during September in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Lupin here.

40
article thumbnail

Cipla sees highest patent filings and grants during September in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Cipla here.

40